ArticleCancer2019
Critical questions in ovarian cancer research and treatment: Report of an American Association for Cancer Research Special Conference.
Article in Cancer, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04812938 (Exploiting Pathogenic Tp53 Mutation for Early Diagnosis of Ovarian Cancer by Mean of Papanicolau Test), which is not on this map. Cited by 35 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Exploiting Pathogenic Tp53 Mutation for Early Diagnosis of Ovarian Cancer by Mean of Papanicolau Test
Who cites it
35 citing papers in PubMed.
- Protein Enrichment from Ascites Fluid Using Nanotrap Hydrogel Particle Technology.Journal of proteome research · 2026Article
- Pharmacological targeting of SF3a1-MDM4 splicing vulnerability in ovarian cancer with rifaximin and antisense oligonucleotide.Journal of translational medicine · 2026Article
- Therapeutic optimization of LIPA targeting to induce endoplasmic reticulum stress and cell death in ovarian cancer.Oncogene · 2026Article
- EC359 Enhances Trametinib Efficacy inBiomolecules · 2025Article
- BCL6 promotes the progression of high-grade serous ovarian cancer cells by inhibiting PLAAT4.Frontiers in pharmacology · 2025Article
- Pharmacological inhibition of the LIF/LIFR autocrine loop reveals vulnerability of ovarian cancer cells to ferroptosis.NPJ precision oncology · 2024Article
- Serum Lipidome Profiling Reveals a Distinct Signature of Ovarian Cancer in Korean Women.Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology · 2024Article
- ATF3 characterizes aggressive drug-tolerant persister cells in HGSOC.Cell death & disease · 2024Article
- Novel LIPA-Targeted Therapy for Treating Ovarian Cancer.Cancers · 2024Article
- Article
- Single CAR-T cell treatment controls disseminated ovarian cancer in a syngeneic mouse model.Journal for immunotherapy of cancer · 2023Article
- Necroptosis-Related Modification Patterns Depict the Tumor Microenvironment, Redox Stress Landscape, and Prognosis of Ovarian Cancer.Oxidative medicine and cellular longevity · 2023Article
- Self-assembling peptides as immunomodulatory biomaterials.Frontiers in bioengineering and biotechnology · 2023Review
- Transcriptomic analyses of ovarian clear-cell carcinoma with concurrent endometriosis.Frontiers in endocrinology · 2023Article
- New Insights into Ferroptosis Initiating Therapies (FIT) by Targeting the Rewired Lipid Metabolism in Ovarian Cancer Peritoneal Metastases.International journal of molecular sciences · 2022Review
- Molecular Analysis of Short- versus Long-Term Survivors of High-Grade Serous Ovarian Carcinoma.Cancers · 2022Article
- Article
- Molecular subtypes, clinical significance, and tumor immune landscape of angiogenesis-related genes in ovarian cancer.Frontiers in oncology · 2022Article
- δ-Tocotrienol sensitizes and re-sensitizes ovarian cancer cells to cisplatin via induction of G1 phase cell cycle arrest and ROS/MAPK-mediated apoptosis.Cell proliferation · 2021Article
- Insights into ovarian cancer care: report from the ANZGOG Ovarian Cancer Webinar Series 2020.Journal of gynecologic oncology · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
43 authors.
Funding
Abstract
Substantial progress has been made in understanding ovarian cancer at the molecular and cellular level. Significant improvement in 5-year survival has been achieved through cytoreductive surgery, combination platinum-based chemotherapy, and more effective treatment of recurrent cancer, and there are now more than 280,000 ovarian cancer survivors in the United States. Despite these advances, long-term survival in late-stage disease has improved little over the last 4 decades. Poor outcomes relate, in part, to late stage at initial diagnosis, intrinsic drug resistance, and the persistence of dormant drug-resistant cancer cells after primary surgery and chemotherapy. Our ability to accelerate progress in the clinic will depend on the ability to answer several critical questions regarding this disease. To assess current answers, an American Association for Cancer Research Special Conference on "Critical Questions in Ovarian Cancer Research and Treatment" was held in Pittsburgh, Pennsylvania, on October 1-3, 2017. Although clinical, translational, and basic investigators conducted much of the discussion, advocates participated in the meeting, and many presentations were directly relevant to patient care, including treatment with poly adenosine diphosphate ribose polymerase (PARP) inhibitors, attempts to improve immunotherapy by overcoming the immune suppressive effects of the microenvironment, and a better understanding of the heterogeneity of the disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.